ANI Pharmaceuticals
ANIP
269 hedge funds and large institutions have $1.87B invested in ANI Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 81 increasing their positions, 85 reducing their positions, and 24 closing their positions.
158% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 24
45% more capital invested
Capital invested by funds: $1.29B → $1.87B (+$581M)
16% more funds holding
Funds holding: 232 → 269 (+37)
2.93% more ownership
Funds ownership: 91.17% → 94.1% (+2.9%)
0% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $2.86M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 85
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.5M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$29.4M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$23.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$22.5M |
| 5 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$76.5M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$21.4M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$20.4M |
| 4 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
-$18.9M |
| 5 |
FGP
Freestone Grove Partners
San Francisco,
California
|
-$13.4M |
ANIP Hedge Fund Activity: Q3 2025 in Review
269 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2025, worth a combined $1.87B — up 45% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new ANIP positions and 24 closed out — a net gain of 38 holders — while 81 added to existing stakes and 85 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $32.5M. The largest seller was Millennium Management, cutting an estimated $76.5M.
- 269 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2025, up from 232 in Q2 2025.
- Funds reported $1.87B of ANI Pharmaceuticals stock for Q3 2025, up 45% quarter-over-quarter.
- 62 funds opened new ANI Pharmaceuticals positions in Q3 2025 and 24 closed out, a net change of +38 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2025 was Point72 Asset Management, an estimated $32.5M added.
- The largest ANI Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $76.5M sold.
Based on aggregated 13F filings for Q3 2025.